Aniket Bankar, MD, discusses why rusfertide is considered a promising therapeutic approach for patients with polycythemia vera.

Hence, just like low haemoglobin levels (less than 13.2 g/dL for men and 11.6 g/dL for women) necessitate medical ...

Protagonist Therapeutics has 2 attractive late-stage pipeline assets, but commercialized sales will not begin until 2027.

Two posters at the CHEST 2024 annual meeting revealed that 18% of eligible patients hospitalized with acute exacerbations of ...

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other ...

An expert explained the importance of education and involvement in care for patients with myeloproliferative neoplasms.

Read on to learn what doctors look for in a routine blood test and what’s considered a healthy PCV range for Male, Female and ...

GlobalData’s report assesses the drugs in the Hepcidin pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline.

Though INCY's performance in the year so far has been good, increasing competition for Jakafi is a concern. We advise ...

Image Source: Zacks Investment Research Incyte’s lead drug, Jakafi, is a JAK1/JAK2 inhibitor approved for the treatment of polycythemia vera (PV) in adults who have had an inadequate response to ...

Ropeginterferon alfa-2b (Ropeg) is approved for the treatment of adults with polycythemia vera (PV). This report aims to analyze the ethnic sensitivity of Ropeg for the treatment of PV, comparing the ...